ESR1 and breast cancer: Regarded as a subtype of breast malignancy, TNBC is featured with a lack of human epidermal growth factor receptor 2 (HER-2), progesterone receptor (PR), and estrogen receptor (ER) expression, accounting for almost 15%-20% of breast cancers [2].